Medicine today is reactive: treatments begin only after symptoms surface. GENOU shifts healthcare from emergency intervention to lifelong risk prediction by unifying whole genome sequencing at birth with serial microbiome profiling, milestone kinetics, and cognitive progression.
0–7 Days
Newborn Baseline Enrollment
360°
Multi-Omics & Cognitive Map
Lifelong
Predictive Risk Trajectory
Integrating whole-genome variant annotations with real-time developmental trajectories.
Closing the Gap in Conventional Newborn Screening
Conventional heel-prick tests detect fewer than 50 biochemical conditions. GENOU combines four data dimensions into one continuously updated digital profile.
Whole Genome / Exome Sequencing (WGS/WES) annotating monogenic risks, polygenic risk scores (PRS), and pharmacogenomics for lifetime drug safety.
Serial stool 16S rRNA / shotgun sequencing to track gut microbial diversity, dysbiosis risk markers, and gut-brain metabolic axes.
Validated digital assessments screening for executive function, sensory integration, memory, and early indicators of ADHD or ASD from age 2 onward.
Our AI engine synthesizes longitudinal growth charts, pediatric vitals, and genetic markers into personalized, proactive clinical care plans.
Research & Insights
Peer-reviewed methodologies powering our early childhood polygenic score algorithms and neurodevelopmental trajectories.
Standard heel-stick tests flag acute metabolic crises but miss risks for juvenile diabetes, cardiac conduction disorders, and drug intolerances.
Tracking bifidobacterial pioneer colonies in infants provides crucial biological windows for preventing autoimmune and neurodevelopmental deficits.
How continuous milestone tracking replaces one-off IQ testing to deliver nuanced insight into working memory and behavioral self-regulation.
Explore our full repository of clinical research, pediatric multi-omics insights, and cognitive progression studies.
Transparent Platform Subscriptions
Every newborn receives an encrypted digital health registry and dynamic risk profile.
Essential WHO growth tracking and standardized neuropsych screening.
Continuous AI risk scoring, microbiome tracking, and specialized clinical reports.
Clinical grade whole-genome sequencing kit dispatched at birth (0-7 days).
GENOU is pioneered by Axiovita Research and Technology Private Limited, incubated under the DRISHTI CPS Foundation at IIT Indore. Our mission is to translate complex genomics and neuroinformatics into accessible, actionable pediatric care.
Dr. Megha Gautam
Founder & CEO, Axiovita Research and Technology
Ambuj Sharma
AI / ML Lead, Axiovita Research and Technology
A child's genome is a lifelong baseline roadmap—not a fixed destiny. By pairing genomic sequencing at birth with real-time phenotypic tracking (nutrition, milestone acquisition, gut microbiome colonization, and cognitive progress), GENOU equips parents and pediatricians with early warnings to intervene years before clinical disease onset.
Strict compliance with Indian DPDP and global HIPAA privacy standards.
Multi-modal risk models backed by peer-reviewed clinical cohorts.